Clinilabs invites you to their event
About this event
Register for our free webinar: What’s New? An Update on Novel Strategies to Treat Schizophrenia
Dr. Leslie Citrome joins us as a guest speaker to inform clinicians and those interested in new developments in the medication treatment of schizophrenia. Dr. Citrome is a clinical professor of behavioral sciences at New York Medical College in Valhalla, NY, and several other esteemed universities throughout the nation. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis, editor emeritus, the International Journal of Clinical Practice where he was editor-in-chief 2013-2019; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology (ASCP) Corner in the Journal of Clinical Psychiatry; among many others.
The key takeaways from this presentation are:
Hosted by
Ms. Jeanine Falinski, VP of Strategy and Corporate Development, has more than 20 years of experience in the pharmaceutical industry. Jeanine graduated from Emerson College with a degree in New Media and Marketing, later on receiving her MBA in Pharmaceutical Management from Drexel University.
Dr. Citrome is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla, New York, clinical professor of psychiatry at SUNY Upstate Medical University, and adjunct clinical professor of psychiatry, Icahn School of Medicine at Mount Sinai in New York City, New York. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American Society of Clinical Psychopharmacology where he currently serves as President. Dr. Citrome obtained his MD degree from the McGill University Faculty of Medicine in 1983 and his MPH degree from the Columbia School of Public Health in 1996 and is currently a consultant in clinical trial design and interpretation.
We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.
